https://www.epo.org/fr/boards-of-appeal/decisions/t970636eu1
T 0636/97 (Erythropoietin II/KIRIN-AMGEN) du 26.03.1998
kirin amgen26 03063697erythropoietin
https://www.epo.org/de/boards-of-appeal/decisions/t970636eu1
T 0636/97 (Erythropoietin II/KIRIN-AMGEN) vom 26.03.1998
kirin amgen26 03063697erythropoietin
https://www.prnewswire.com/news-releases/amgen-and-kyowa-kirin-provide-top-line-results-from-rocatinlimab-phase-3-ignite-study-in-adults-with-moderate-to-severe-atopic-dermatitis-302396130.html
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS...
/PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical...
https://www.amgen.com/newsroom/press-releases/2021/06/amgen-and-kyowa-kirin-to-jointly-develop-and-commercialize-khk4083-a-phase-3ready-potential-firstinclass-treatment-for-atopic-dermatitis
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential...
https://www.epo.org/de/boards-of-appeal/decisions/t940656eu1
T 0656/94 (Colony-stimulating factor/KIRIN-AMGEN) vom 16.07.1998
colony stimulating factor